Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Investigate Etokimab (ANB020) in Adult Subjects With Chronic Rhinosinusitis With Nasal Polyposis

Next Previous
Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Investigate Etokimab (ANB020) in Adult Subjects With Chronic Rhinosinusitis With Nasal Polyposis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etokimab (Primary)
  • Indications Nasal polyps; Rhinosinusitis
  • Focus Therapeutic Use
  • Acronyms ECLIPSE
  • Sponsors AnaptysBio

    • Most Recent Events

    • 25 Feb 2021 Status changed from active, no longer recruiting to discontinued, according to an AnaptysBio media release.
    • 25 Feb 2021 According to an AnaptysBio media release, the company further development of etokimab following review of topline week 16 data from the approximately 100-patient where patient failed to achieve statistically significant over placebo on either co-primary endpoint.
    • 10 Aug 2020 According to an AnaptysBio media release, the company intends to determine next steps for the etokimab program after reviewing complete data from this trial, including week 16 primary endpoint data by year-end 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top